Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
Collections
Source
Journal of Clinical Oncology